Scientists identify tau protein hotspot that drives dementia progression

Tau proteins in the brain are supposed to stay soluble and functional, but in Alzheimer's disease and frontotemporal dementia, something goes wrong. They misfold, clump together into tangles inside neurons, and the cells die. For decades, researchers have watched this happen without fully understanding the mechanism—how misfolded tau convinces healthy tau to join the mess, how thousands of shapeless protein molecules somehow find each other and stack in perfect alignment, like a tower of poker chips thousands high. A team led by Northwestern University chemist Songi Han, working with collaborators at UC Santa Barbara, has now identified the answer: a single dominant hotspot on the tau protein where the conversion begins.

The discovery hinges on water. Tau proteins, like all proteins in cells, are surrounded by water molecules. But water doesn't interact with every part of the protein equally. Some regions attract water readily. Others repel it—these are called hydrophobic regions. Han's team found something unusual at the hotspots within tau's hydrophobic zones: water molecules form a dynamic cap, something like ice but with molecules that remain fluid and mobile. These caps mark the precise spot where two tau molecules will meet and bind.

When a misfolded tau protein encounters a healthy one, or when it approaches the end of an existing fibril, the hotspots align. The protective water caps are released, and the energy freed by that release locks the two proteins together. This ensures they line up the same way every time, propagating the misfolded shape down the chain. To test this, the researchers chemically tagged the hotspot and watched the fibrils stop growing. When they tagged two other sites away from the hotspot, growth continued unimpeded. The hotspot is the linchpin.

Songi Han, who holds the Mark and Nancy Ratner Professorship of Chemistry at Northwestern's Weinberg College of Arts and Sciences, sees the practical implications immediately. "Once you know that aggregation-prone tau proteins always have a hotspot that is first attracted to the same site of tau that is stacked to fibrils, then you know there's always some part of the protein that you can target to neutralize," she said. Instead of searching blindly across the entire protein for a way to intervene, scientists now have a specific address. Block that hotspot, and you block propagation.

The research, which will be published October 16 in the Proceedings of the National Academy of Sciences, opens two distinct therapeutic pathways. The first is direct: develop drugs that bind to the hotspot and prevent misfolded tau from recruiting healthy tau. The second is foundational: understanding how tau works at the molecular level makes it possible to create synthetic tau fibrils that mimic the various tauopathies. Right now, researchers lack good disease models. They cannot easily make synthetic fibrils that behave like those found in Alzheimer's patients or those with frontotemporal dementia. This forces them to work with human tissue, which is scarce and difficult to obtain. Synthetic models would accelerate drug development and allow researchers to test interventions rationally rather than by trial and error.

Han emphasized the broader significance. "In order to cure a disease, one needs to be able to recreate it," she said. "There's a real problem that disease-mimicking tau fibrils cannot be synthetically made easily." This study provides the molecular blueprint. By understanding exactly how tau misfolds and propagates, researchers can now build synthetic versions that behave like the real thing. The work was supported by the National Institutes of Health, the Tau Consortium of the Rainwater Charitable Fund, the German Research Foundation, the W. M. Keck Foundation, and the National Science Foundation.

The implications extend beyond tau. Once scientists understand how one protein misfolds and recruits others, they can apply the same logic to other neurodegenerative diseases driven by protein aggregation. For now, the field has a concrete target and a clearer path forward.